Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates
- PMID:15237854
- DOI: 10.1081/dmr-120034000
Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates
Abstract
Cytochrome P450 2D6 (CYP2D6) is the first well-characterized polymorphic phase I drug-metabolizing enzyme, and more than 80 allelic variants have been identified for the CYP2D6 gene, located on human chromosome 22q13.1. Human debrisoquine and sparteine metabolism is subdivided into two principal phenotypes--extensive metabolizer and poor metabolizer--that arise from variant CYP2D6 genotypes. It has been estimated that CYP2D6 is involved in the metabolism and disposition of more than 20% of prescribed drugs, and most of them act in the central nervous system or on the heart. These drug substrates are characterized as organic bases containing one nitrogen atom with a distance about 5, 7, or 10 A from the oxidation site. Aspartic acid 301 and glutamic acid 216 were determined as the key acidic residues for substrate-enzyme binding through electrostatic interactions. CYP2D6 transgenic mice, generated using a lambda phage clone containing the complete wild-type CYP2D6 gene, exhibits enhanced metabolism and disposition of debrisoquine. This transgenic mouse line and its wild-type control are models for human extensive metabolizers and poor metabolizers, respectively, and would have broad application in the study of CYP2D6 polymorphism in drug discovery and development, and in clinical practice toward individualized drug therapy. Endogenous 5-methoxyindole- thylamines derived from 5-hydroxytryptamine were identified as high-affinity substrates of CYP2D6 that catalyzes their O-demethylations with high enzymatic capacity and specificity. Thus, polymorphic CYP2D6 may play an important role in the interconversions of these psychoactive tryptamines, including a crucial step in a serotonin-melatonin cycle.
Similar articles
- Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.Shen HW, Wu C, Jiang XL, Yu AM.Shen HW, et al.Biochem Pharmacol. 2010 Jul 1;80(1):122-8. doi: 10.1016/j.bcp.2010.02.020. Epub 2010 Mar 3.Biochem Pharmacol. 2010.PMID:20206139Free PMC article.
- Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.Zanger UM, Raimundo S, Eichelbaum M.Zanger UM, et al.Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37. doi: 10.1007/s00210-003-0832-2. Epub 2003 Nov 15.Naunyn Schmiedebergs Arch Pharmacol. 2004.PMID:14618296Review.
- Cytochrome P450: genetic polymorphism and drug interactions.Belpaire FM, Bogaert MG.Belpaire FM, et al.Acta Clin Belg. 1996;51(4):254-60. doi: 10.1080/22953337.1996.11718518.Acta Clin Belg. 1996.PMID:8858891
- Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.Neafsey P, Ginsberg G, Hattis D, Sonawane B.Neafsey P, et al.J Toxicol Environ Health B Crit Rev. 2009;12(5-6):334-61. doi: 10.1080/10937400903158342.J Toxicol Environ Health B Crit Rev. 2009.PMID:20183526Review.
- Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.Neul C, Hofmann U, Schaeffeler E, Winter S, Klein K, Giacomini KM, Eichelbaum M, Schwab M, Nies AT.Neul C, et al.Br J Pharmacol. 2021 Mar;178(6):1459-1474. doi: 10.1111/bph.15370. Epub 2021 Feb 23.Br J Pharmacol. 2021.PMID:33434947
Cited by
- Lentiviral transgenic microRNA-based shRNA suppressed mouse cytochromosome P450 3A (CYP3A) expression in a dose-dependent and inheritable manner.Wang Y, Hu HH, Pang H, Zhou XY, Yu LS, Wang LL, Liu C, Guo KN, Zhao C, Liu Q, Zeng BH, Tang H, Shang HT, Zeng S, Wei H.Wang Y, et al.PLoS One. 2012;7(1):e30560. doi: 10.1371/journal.pone.0030560. Epub 2012 Jan 24.PLoS One. 2012.PMID:22291988Free PMC article.
- Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.Jiang XL, Shen HW, Mager DE, Yu AM.Jiang XL, et al.Drug Metab Dispos. 2013 May;41(5):975-86. doi: 10.1124/dmd.112.050724. Epub 2013 Feb 7.Drug Metab Dispos. 2013.PMID:23393220Free PMC article.
- DrugMetZ DB: an anthology of human drug metabolizing Chytochrome P450 enzymes.Antony TR, Nagarajan S.Antony TR, et al.Bioinformation. 2006 Nov 14;1(7):248-50. doi: 10.6026/97320630001248.Bioinformation. 2006.PMID:17597900Free PMC article.
- Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism.Deodhar M, Turgeon J, Michaud V.Deodhar M, et al.Pharmaceutics. 2021 Sep 14;13(9):1466. doi: 10.3390/pharmaceutics13091466.Pharmaceutics. 2021.PMID:34575542Free PMC article.Review.
- CYP2D6 genotype may moderate measures of brain structure in methamphetamine users.Dean AC, Nurmi EL, Morales AM, Cho AK, Seaman LC, London ED.Dean AC, et al.Addict Biol. 2021 May;26(3):e12950. doi: 10.1111/adb.12950. Epub 2020 Aug 6.Addict Biol. 2021.PMID:32767519Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources